A 6-year trend of the healthcare costs of arthritis in a population-based cohort of older women

Objective: To provide an accurate representation of the economic burden of arthritis by estimating the adjusted incremental healthcare cost of arthritis at multiple percentiles and reporting the cost trends across time. Methods: A healthcare cost study based on health survey and linked administrative data, where costs were estimated from the government's perspective in dollars per person per year. Quantile regression was used to estimate the adjusted incremental cost at the 25th, 50th, 75th, 90th, and 95th percentiles. Results: Data from 4287 older Australian women were included. The median incremental healthcare cost of arthritis was, in 2012 Australian dollars, $480 (95% CI: $498–759) in 2009; however, 5% of individuals had 5-times higher costs than the ‘average individual’ with arthritis. Healthcare cost of arthritis did not increase significantly from 2003 to 2009. Conclusion: Healthcare cost of arthritis represents a substantial burden for the governments. Future research should continue to monitor the economic burden of arthritis.

[1]  M. Leach,et al.  Health care utilization among young Australian women with severe tiredness: Results from the Australian Longitudinal Study on Women's Health (ALSWH) , 2017, Health care for women international.

[2]  J. Byles,et al.  Factors associated with higher healthcare costs in individuals living with arthritis: evidence from the quantile regression approach , 2015, Expert review of pharmacoeconomics & outcomes research.

[3]  J. Byles,et al.  Anticholinergic burden in older women: not seeing the wood for the trees? , 2015, The Medical journal of Australia.

[4]  G. Mishra.  Australian Longitudinal Study on Women's Health , 2014 .

[5]  Saad Rais,et al.  High-cost users of Ontario's healthcare services. , 2013, Healthcare policy = Politiques de sante.

[6]  J. Verho,et al.  Drug expenditure of high-cost patients and their characteristics in Finland , 2013, The European Journal of Health Economics.

[7]  A. Forsythe,et al.  Comorbidity Burden, Healthcare Resource Utilization, and Costs in Chronic Gout Patients Refractory to Conventional Urate-Lowering Therapy , 2012, American journal of therapeutics.

[8]  L. Herrinton,et al.  Direct medical expenditure associated with rheumatoid arthritis in a nationally representative sample from the medical expenditure panel survey , 2012, Arthritis care & research.

[9]  Cost of rheumatic disorders in the Netherlands. , 2012, Best practice & research. Clinical rheumatology.

[10]  E. Soriano,et al.  Cost of rheumatoid arthritis in a selected population from Argentina in the prebiologic therapy era , 2012, ClinicoEconomics and outcomes research : CEOR.

[11]  J. Stoltzfus,et al.  Why quantile regression makes good sense for analyzing economic outcomes in medical research. , 2012, Academic emergency medicine : official journal of the Society for Academic Emergency Medicine.

[12]  Yue Zhang,et al.  Residential long-term care capacity planning: the shortcomings of ratio-based forecasts. , 2012, Healthcare policy = Politiques de sante.

[13]  R. Goeree,et al.  The excess burden of osteoarthritis in the province of Ontario, Canada. , 2012, Arthritis and rheumatism.

[14]  T. Le,et al.  Health care costs in US patients with and without a diagnosis of osteoarthritis , 2012, Journal of pain research.

[15]  A. Dobson,et al.  The value of time in longitudinal studies of ageing. Lessons from the Australian Longitudinal Study on Women's Health , 2011, Australasian journal on ageing.

[16]  S. Morgan,et al.  Population aging and the determinants of healthcare expenditures: the case of hospital, medical and pharmaceutical care in british columbia, 1996 to 2006. , 2011, Healthcare policy = Politiques de sante.

[17]  L. Jacobsson,et al.  Cost of Illness from the Public Payers’ Perspective in Patients with Ankylosing Spondylitis in Rheumatological Care , 2010, The Journal of Rheumatology.

[18]  Wayne Swan,et al.  Australia to 2050: future challenges , 2010 .

[19]  Jennifer M. Hootman,et al.  Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation --- United States, 2007-2009. , 2010, MMWR. Morbidity and mortality weekly report.

[20]  S. Silverman,et al.  Burden of Fibromyalgia and Comparisons With Osteoarthritis in the Workforce , 2009, Journal of occupational and environmental medicine.

[21]  E. Banks,et al.  Is inequity undermining Australia's ‘universal’ health care system? Socio‐economic inequalities in the use of specialist medical and non‐medical ambulatory health care , 2009, Australian and New Zealand journal of public health.

[22]  Rachelle Buchbinder,et al.  Guideline for the non-surgical management of hip and knee osteoarthritis , 2009 .

[23]  E. Krishnan,et al.  Disease-Related and All-Cause Health Care Costs of Elderly Patients With Gout , 2008, Journal of managed care pharmacy : JMCP.

[24]  W. Lems,et al.  Decreasing incidence of symptomatic gastrointestinal ulcers and ulcer complications in patients with rheumatoid arthritis , 2007, Annals of the rheumatic diseases.

[25]  Stefan Felder,et al.  Population ageing and health care expenditure: a school of 'red herrings'? , 2007, Health economics.

[26]  Edward H. Yelin,et al.  National and state medical expenditures and lost earnings attributable to arthritis and other rheumatic conditions--United States, 2003. , 2007, MMWR. Morbidity and mortality weekly report.

[27]  Joel W. Cohen,et al.  Prescription drugs and the changing concentration of health care expenditures. , 2007, Health affairs.

[28]  D. Preen,et al.  High‐cost users of hospital beds in Western Australia: a population‐based record linkage study , 2006, The Medical journal of Australia.

[29]  Wendy J Brown,et al.  Cohort Profile: the Australian Longitudinal Study on Women's Health. , 2005, International journal of epidemiology.

[30]  Anirban Basu,et al.  Generalized Modeling Approaches to Risk Adjustment of Skewed Outcomes Data , 2003, Journal of health economics.

[31]  M. Braun,et al.  Infectious complications of biologic treatments of rheumatoid arthritis , 2003, Current opinion in rheumatology.

[32]  L. Laine.  The gastrointestinal effects of nonselective NSAIDs and COX-2-selective inhibitors. , 2002, Seminars in arthritis and rheumatism.

[33]  S. Felder,et al.  Ageing of population and health care expenditure: a red herring? , 1999, Health economics.

[34]  A J Dobson,et al.  Women's Health Australia: on the progress of the main cohort studies. , 1999, Journal of women's health & gender-based medicine.

[35]  Annette J. Dobson,et al.  Women's Health Australia: Establishment of The Australian Longitudinal Study on Women's Health , 1996 .

[36]  S. Perry.  Reports from the Australian Institute of Health and Welfare (AIHW) , 1995, International Journal of Technology Assessment in Health Care.

[37]  P. Tugwell,et al.  The use of disease modifying antirheumatic drugs in the management of rheumatoid arthritis. , 1989, Postgraduate medical journal.

[38]  W. S. Clark.  The treatment of rheumatoid arthritis. , 1949, The Medical clinics of North America.